Basil Abdin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Basil Abdin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Ayman Jaber Hammoudeh
Department of Cardiology, Istishari Hospital, Amman 11184, Jordan
2 shared publications - Hanna Al-Makhamreh
Consultant Cardiologist at Jordan University Hospital
2 shared publications - Abdelrahman F. Obiedat
School of Medicine, The University of Jordan, Amman, Jordan
1 shared publication Abed AlFattah AlNsour
Internal Medicine, Jordanian Royal Medical Services, Amman, JOR
1 shared publication- Ahmad Y. Al-Omari
Department of General Surgery, Jordan University Hospital, Amman, Jordan
1 shared publication - Ala Shaban
King Hussein Cancer Center, Amman 11941, Jordan
1 shared publication
Latest Publications
- Open Access
The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study – A Prospective Cohort Study
Objective: Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the prevalence of comorbidities among Middle Eastern patients with AF and their impact on clinical outcomes are scarce. This study aimed to assess the impact of comorbidities in a Middle Eastern population with AF treated with contemporary anticoagulation. Design: Prospective observational cohort study. Setting: Patients from 20 hospitals and 30 outpatient cardiology clinics across Jordan were enrolled from May 2019 through October 2020. Participants: 2020 consecutive patients were enrolled. 117 of them were lost to follow-up, and 1903 had available data for analysis. Of the total, 1096 (54.3%) patients were women, and 924 (45.7%) were men. Eligible patients were 18 years of age or above, had a confirmed AF diagnosis and provided informed consent. Primary and secondary outcomes: We are examining the outcomes of patients with AF, comparing those who have multimorbidities versus oligomorbidities. The primary outcomes were AF-related complications occurring within 1-year follow-up: major bleeding, non-major bleeding, stroke/cerebrovascular accidents, systemic emboli and acute coronary syndrome. Secondary outcomes included causes of death among deceased patients. Results: Among the cohort, 1160 (57.4%) had two or less comorbidities (oligomorbidity group) and 860 (42.6%) had three or more comorbidities (multimorbidity group). Compared with the oligomorbidity group, the multimorbidity group had significantly higher rates of hypertension (97.9% vs 57.2%), diabetes mellitus type II (92.4% vs 7.3%), cardiovascular disease (100% vs 79.6%), chronic kidney disease (18.4% vs 1.8%) and chronic lung disease (7% vs 1%, p<0.001 for all comparisons). Over the 1-year follow-up, the multimorbidity group experienced higher rates of hospitalisation (24% vs 16.9%, p<0.001), all-cause death (21.4% vs 9.5%, p<0.001) and cardiovascular death (11.8% vs 4.7%, p=0.002) than the oligomorbidity group. All-cause mortality in the multimorbid group was mostly related to hypertension with an OR of 5.5 (95% CI 2.07 to 14.73), history of stroke (OR 2.7, 95% CI1.85–4.03) and heart failure (OR 2.3, 95% CI 1.64 to 3.33). However, the use of warfarin (OR 0.6, 95% CI 0.38 to 0.82) and novel oral anticoagulants (OR 0.7, 95% CI 0.46 to 0.91) had protective effects from all-cause mortality. Conclusion: Middle Eastern patients with AF appear to exhibit a high burden of comorbidities. The results suggest the more comorbidities in these patients, the higher the rates of hospitalisation and death. Trial registration number: NCT03917992 .
Open AccessThe Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study – A Prospective Cohort Study
Objective: Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the prevalence of comorbidities among Middle Eastern patients with AF and their impact on clinical outcomes are scarce. This study aimed to assess the impact of comorbidities in a Middle Eastern population with AF treated with contemporary anticoagulation. Design: Prospective observational cohort study. Setting: Patients from 20 hospitals and 30 outpatient cardiology clinics across Jordan were enrolled from May 2019 through October 2020. Participants: 2020 consecutive patients were enrolled. 117 of them were lost to follow-up, and 1903 had available data for analysis. Of the total, 1096 (54.3%) patients were women, and 924 (45.7%) were men. Eligible patients were 18 years of age or above, had a confirmed AF diagnosis and provided informed consent. Primary and secondary outcomes: We are examining the outcomes of patients with AF, comparing those who have multimorbidities versus oligomorbidities. The primary outcomes were AF-related complications occurring within 1-year follow-up: major bleeding, non-major bleeding, stroke/cerebrovascular accidents, systemic emboli and acute coronary syndrome. Secondary outcomes included causes of death among deceased patients. Results: Among the cohort, 1160 (57.4%) had two or less comorbidities (oligomorbidity group) and 860 (42.6%) had three or more comorbidities (multimorbidity group). Compared with the oligomorbidity group, the multimorbidity group had significantly higher rates of hypertension (97.9% vs 57.2%), diabetes mellitus type II (92.4% vs 7.3%), cardiovascular disease (100% vs 79.6%), chronic kidney disease (18.4% vs 1.8%) and chronic lung disease (7% vs 1%, p<0.001 for all comparisons). Over the 1-year follow-up, the multimorbidity group experienced higher rates of hospitalisation (24% vs 16.9%, p<0.001), all-cause death (21.4% vs 9.5%, p<0.001) and cardiovascular death (11.8% vs 4.7%, p=0.002) than the oligomorbidity group. All-cause mortality in the multimorbid group was mostly related to hypertension with an OR of 5.5 (95% CI 2.07 to 14.73), history of stroke (OR 2.7, 95% CI1.85–4.03) and heart failure (OR 2.3, 95% CI 1.64 to 3.33). However, the use of warfarin (OR 0.6, 95% CI 0.38 to 0.82) and novel oral anticoagulants (OR 0.7, 95% CI 0.46 to 0.91) had protective effects from all-cause mortality. Conclusion: Middle Eastern patients with AF appear to exhibit a high burden of comorbidities. The results suggest the more comorbidities in these patients, the higher the rates of hospitalisation and death. Trial registration number: NCT03917992 .
- Open Access
- 26 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e26337
Perspectives on COVID-19 Vaccines and Its Hesitancy Among Jordanian Population
Since the spread of the COVID-19 virus, governments are putting significant resources into ending the pandemic. Vaccination arises as the best solution to get back to our everyday lives. However, we are now facing vaccine hesitancy, which is a critical problem. This cross-sectional study was conducted between December 15, 2020, and March 1, 2021, using a validated online-based questionnaire; participants were compared using the Statistical Package for the Social Sciences (SPSS) program based on multiple factors. A total of 1607 participants throughout Jordan have responded to the questionnaire, among which 880 (54.8%) have bachelor's degrees, 236 (14.7%) have a high educational level (master and doctoral), and 491 (30.5%) have a diploma or less. Although this is a non-probable sample, it is not a representative sample as, according to United Nations Educational, Scientific and Cultural Organization (UNESCO), only 33.6% of the Jordan population have a tertiary education. Overall, 892 (55.5%) of the studied subjects had the intention to take the vaccine, distributed as follows: 156 (66.1%) of the high educational participants wanted to take the vaccine, compared to 512 (58.2%) of those who have bachelor’s degree and 224 (45.6%) of those who have diploma or less (p < 0.001). Reading scientific articles talking about the vaccines and their effects (55.6%, p < 0.001), knowing the mechanism of action (45.2%, p = 0.007), getting proper medical advice (27.2%, p < 0.001), encouraged by the increasing number of infections and deaths (39.7%, p < 0.001), and the number of people who received the vaccine (16.1%, p < 0.001) were the most critical factors that played a role in taking the vaccine by all of the studied groups. Male gender (OR = 2.02; 95% CI = 1.54-2.64; p < 0.001), high income of more than 1000 JDs (1400 USD) (OR = 3.23; 95% CI = 2.21-4.71; p < 0.001), having an educational level of either high education (OR = 3.39; 95% CI = 2.07-5.55; p < 0.001) or bachelor degree (OR = 1.67; 95% CI = 1.25-2.24; p = 0.001), and being encouraged by the increasing number of infections and deaths caused by COVID-19 (OR = 1.97; 95% CI = 1.46-2.66; p < 0.001) were all significantly associated with the willingness to take the vaccine. As the world rushes toward vaccination to end the pandemic, efforts are needed to end this phenomenon of vaccine hesitancy by enlightening people with the precise knowledge regarding the vaccine's mechanism of action, side effects, and efficacy focusing mainly on people with lower educational levels.
- 26 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e26337
Open AccessPerspectives on COVID-19 Vaccines and Its Hesitancy Among Jordanian Population
Since the spread of the COVID-19 virus, governments are putting significant resources into ending the pandemic. Vaccination arises as the best solution to get back to our everyday lives. However, we are now facing vaccine hesitancy, which is a critical problem. This cross-sectional study was conducted between December 15, 2020, and March 1, 2021, using a validated online-based questionnaire; participants were compared using the Statistical Package for the Social Sciences (SPSS) program based on multiple factors. A total of 1607 participants throughout Jordan have responded to the questionnaire, among which 880 (54.8%) have bachelor's degrees, 236 (14.7%) have a high educational level (master and doctoral), and 491 (30.5%) have a diploma or less. Although this is a non-probable sample, it is not a representative sample as, according to United Nations Educational, Scientific and Cultural Organization (UNESCO), only 33.6% of the Jordan population have a tertiary education. Overall, 892 (55.5%) of the studied subjects had the intention to take the vaccine, distributed as follows: 156 (66.1%) of the high educational participants wanted to take the vaccine, compared to 512 (58.2%) of those who have bachelor’s degree and 224 (45.6%) of those who have diploma or less (p < 0.001). Reading scientific articles talking about the vaccines and their effects (55.6%, p < 0.001), knowing the mechanism of action (45.2%, p = 0.007), getting proper medical advice (27.2%, p < 0.001), encouraged by the increasing number of infections and deaths (39.7%, p < 0.001), and the number of people who received the vaccine (16.1%, p < 0.001) were the most critical factors that played a role in taking the vaccine by all of the studied groups. Male gender (OR = 2.02; 95% CI = 1.54-2.64; p < 0.001), high income of more than 1000 JDs (1400 USD) (OR = 3.23; 95% CI = 2.21-4.71; p < 0.001), having an educational level of either high education (OR = 3.39; 95% CI = 2.07-5.55; p < 0.001) or bachelor degree (OR = 1.67; 95% CI = 1.25-2.24; p = 0.001), and being encouraged by the increasing number of infections and deaths caused by COVID-19 (OR = 1.97; 95% CI = 1.46-2.66; p < 0.001) were all significantly associated with the willingness to take the vaccine. As the world rushes toward vaccination to end the pandemic, efforts are needed to end this phenomenon of vaccine hesitancy by enlightening people with the precise knowledge regarding the vaccine's mechanism of action, side effects, and efficacy focusing mainly on people with lower educational levels.
- Open Access
- 19 May 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (10) , 6173
Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study
(1) Background: Atrial fibrillation (AF) is the most common arrhythmia causing an increased risk of mortality and morbidity. It is classified into paroxysmal and non-paroxysmal AF depending on the duration and frequency of the episodes. (2) Aims: Our goal was to investigate and compare the clinical profiles, risk of co-morbidities, the use of oral anticoagulation, and outcomes of patients with paroxysmal and non-paroxysmal AF in inpatient and outpatient settings. (3) Methods: Data were extracted from 28 different hospitals and centers in Jordan with a total of 2160 patients enrolled in the study using an observational non-interventional study model. The clinical features and the use of oral anticoagulants were compared in patients with paroxysmal and non-paroxysmal AF. (4) Results: Paroxysmal AF was documented in 35.6% (769) of the patients and non-paroxysmal types in 63.9% (1380); in addition, the type of AF was unknown in 11 (0.5%) patients. Our results showed that non-paroxysmal AF patients tend to be older with more co-morbidities and higher CHA2DS2-VASC and HAS-BLED scores. They also have higher rates of hypertension and diabetes. Anticoagulant, antiarrhythmic, and diuretic agents, overall, were used more in non-paroxysmal AF than paroxysmal AF. Hospital admissions were also more frequent in non-paroxysmal AF due to various factors, some of which are heart failure, bleeding risk, and COPD. (5) Conclusions: Non-paroxysmal AF is more common among Jordanian AF patients. The prevalence of comorbidities and the use of different types of therapies, especially anticoagulants, were higher in these patients.
- 19 May 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (10) , 6173
Open AccessParoxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study
(1) Background: Atrial fibrillation (AF) is the most common arrhythmia causing an increased risk of mortality and morbidity. It is classified into paroxysmal and non-paroxysmal AF depending on the duration and frequency of the episodes. (2) Aims: Our goal was to investigate and compare the clinical profiles, risk of co-morbidities, the use of oral anticoagulation, and outcomes of patients with paroxysmal and non-paroxysmal AF in inpatient and outpatient settings. (3) Methods: Data were extracted from 28 different hospitals and centers in Jordan with a total of 2160 patients enrolled in the study using an observational non-interventional study model. The clinical features and the use of oral anticoagulants were compared in patients with paroxysmal and non-paroxysmal AF. (4) Results: Paroxysmal AF was documented in 35.6% (769) of the patients and non-paroxysmal types in 63.9% (1380); in addition, the type of AF was unknown in 11 (0.5%) patients. Our results showed that non-paroxysmal AF patients tend to be older with more co-morbidities and higher CHA2DS2-VASC and HAS-BLED scores. They also have higher rates of hypertension and diabetes. Anticoagulant, antiarrhythmic, and diuretic agents, overall, were used more in non-paroxysmal AF than paroxysmal AF. Hospital admissions were also more frequent in non-paroxysmal AF due to various factors, some of which are heart failure, bleeding risk, and COPD. (5) Conclusions: Non-paroxysmal AF is more common among Jordanian AF patients. The prevalence of comorbidities and the use of different types of therapies, especially anticoagulants, were higher in these patients.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Clinical factors predicting asymptomatic atrial fibrillation in Middle Eastern patients
Introduction: Anticoagulation has been shown to be highly effective in stroke prevention in patients who have atrial fibrillation (AF). Many patients with AF do not have symptoms and may not seek medical attention. In this study we evaluated the clinical profiles of asymptomatic AF (AAF) patients and compared them to symptomatic ones to find what factors are associated with absence of symptoms. Methods: We analyzed data of 2000 patients enrolled in the prospective multicenter Jordan AF study from May 2019 to October 2020. Symptoms included palpitations (43%), shortness of breath (34%), fatigue (21%), dizziness (11%), chest pain (2%) or syncope (2%) versus no symptoms (30%, n=591). Findings: The average age of the whole group was 67.7±10.2 years and 47% were males. Clinical factors investigated in relation to absence of symptoms are presented in the attached table Conclusion: AAF is associated with the following clinical features: male gender, age above 59 years, diabetes mellitus (DM), cerebrovascular accident (CVA), and chronic renal failure (CRF), CHA2DS2VASC score of 3 and above and HASBLED score of 3 and above, while first episode and paroxysmal AF (PAF) were more likely to be symptomatic. Individuals with these features should be closely evaluated for AAF by means such as pulse monitoring, smart devices and electrocardiogram. Funding Acknowledgement: Type of funding sources: None.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Clinical factors predicting asymptomatic atrial fibrillation in Middle Eastern patients
Introduction: Anticoagulation has been shown to be highly effective in stroke prevention in patients who have atrial fibrillation (AF). Many patients with AF do not have symptoms and may not seek medical attention. In this study we evaluated the clinical profiles of asymptomatic AF (AAF) patients and compared them to symptomatic ones to find what factors are associated with absence of symptoms. Methods: We analyzed data of 2000 patients enrolled in the prospective multicenter Jordan AF study from May 2019 to October 2020. Symptoms included palpitations (43%), shortness of breath (34%), fatigue (21%), dizziness (11%), chest pain (2%) or syncope (2%) versus no symptoms (30%, n=591). Findings: The average age of the whole group was 67.7±10.2 years and 47% were males. Clinical factors investigated in relation to absence of symptoms are presented in the attached table Conclusion: AAF is associated with the following clinical features: male gender, age above 59 years, diabetes mellitus (DM), cerebrovascular accident (CVA), and chronic renal failure (CRF), CHA2DS2VASC score of 3 and above and HASBLED score of 3 and above, while first episode and paroxysmal AF (PAF) were more likely to be symptomatic. Individuals with these features should be closely evaluated for AAF by means such as pulse monitoring, smart devices and electrocardiogram. Funding Acknowledgement: Type of funding sources: None.